Long-term efficacy and safety of intra-articular sodium hyaluronate (Hyalgan®) in patients with osteoarthritis of the knee

Clinical and Experimental Rheumatology

Volumn 21, Issue 3, 2003, Pages 307-311

  Neustadt, David H ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Hyalgan ; Osteoarthritis of the knee; Sodium hyaluronate

Indexed keywords

ANALGESIC AGENT; HYALURONIC ACID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; KNEE OSTEOARTHRITIS; KNEE PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PAIN ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN BRUISING; SKIN MANIFESTATION; TOTAL KNEE REPLACEMENT; TREATMENT FAILURE; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RANGE OF MOTION, ARTICULAR; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037534440     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. HASCALL VC, LAURENT TC: Hyaluronan: structure and physical properties. Available at: http://www.glycoforum.gr.jp/science/hyaluronan/HA01/HA01E.html. Accessed 2001 May 16, 2001.
2. LAURENT TC, FRASER JR: Hyaluronan. FASEB J 1992; 6: 2397-404.
3. DAHL LB, DAHL IMS, ENGSTROM A, GRANATH K: Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis 1985; 44: 817-22.
4. HYALGAN® PREMARKET APPROVAL APPLICATION: Summary of safety and effectiveness. Available at: http://www.fda.gov/cdrh-pdf/p950027.pdf. Accessed August 22, 2000.
5. SYNVISC® PREMARKET APPROVAL APPLICATION: Summary of Safety and Effectiveness Data. Available at: http://www.fda.gov/cdrh/pdf/p940015.pdf. Accessed August 22, 2000.
6. SYNVISC® [prescribing information]. Philadelphia, PA, Wyeth-Ayerst; 2000.
7. HYALGAN® [prescribing information]. New York, NY, Sanofi Pharmaceuticals, Inc. 2001.
8. BALAZS EA, DENLINGER JL: Viscosupplementation: A new concept in the treatment of osteoarthritis. J Rheumatol 1993; 39 (Suppl.): 3-9.
9. AMERICAN COLLEGE OF RHEUMATOLOGY SUBCOMMITTEE ON OSTEOARTHRITIS GUIDELINES: Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000; 43: 1905-15.
10. ALTMAN RD, MOSKOWITZ R and the Hyalgan Study Group: Intraarticular sodium hyaluronate (Hyalgan®) in the treatment of patients with osteoarthritis of the knee: A randomized clinical trial. J Rheumatol 1998; 25: 2203-12.
11. DOUGADOS M, NGUYEN M, LISTRAT V, AMOR B: High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: A 1 year placebo-controlled trial. Osteoarthritis Cartilage 1993; 1: 97-103.
12. HUSKISSON EC, DONNELLY S: Hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology 1999; 38: 602-7.
13. CARRABBA M, PARESCE E, ANGELINI M, RE KA, TORCHIANA EEM, PERBELLINI A: The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm 1995; 15: 25-31.
14. KOTZ R, KOLARZ G: Intra-articular hyaluronic acid: Duration of effect and results of repeated treatment cycles. Am J Orthop 1999; 28 (Suppl. 11): 5-7.
15. SCALI JJ: Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: A long term study. Eur J Rheum Inflamm 1995; 15: 57-62.